Cryopyrin-associated periodic syndromes: Development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2531-2543

  Hoffman, Hal M ^a   Wolfe, Frederick ^b   Belomestnov, Pavel ^c   Mellis, Scott J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cryopyrin associated periodic syndromes; Daily health assessment form; Outcomes instrument

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RILONACEPT;

ADOLESCENT; ARTHRALGIA; ARTICLE; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DISORDER; CHILL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; DAILY HEALTH ASSESSMENT FORM; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; EYE PAIN; FATIGUE; FEVER; HEADACHE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SELF REPORT; SWEATING; SYMPTOMATOLOGY; TEST RETEST RELIABILITY; THIRST; VALIDATION PROCESS;

CARRIER PROTEINS; HUMANS; INFLAMMATION; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 53349153623     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802297495     Document Type: Article

References (33)

1. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5
2. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203
3. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8
4. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003;15:61-9
5. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001;108:615-20
6. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
7. Aksentijevich I, Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-5
8. Neven B. CINCA syndrome. 2007. Available at: http://www.orpha.net/static/ GB/cinca_syndrome.html [Accessed 4/10/2007]
9. O'Connell SM, O'Regan GM, Bolger T, et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007;24:85-9
10. Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy 2005;4:77-80
11. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7
12. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
13. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New Engl J Med 2006;355:581-92
14. Canna S, Gelabert A, Aksentijevich I, et al. Treatment of 4 patients with cryopyrin-associated periodic syndromes with the long acting IL-1 inhibitor IL-TRAP. Ann Rheum Dis 2005;64(Suppl 3):106
15. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndrome: results from two sequential placebo-controlled studies. Arthritis Rheum 2008 [in press]
16. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-23
17. Wolfe F Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004; 50:3296-305
18. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5
19. Wolfe F, Rasker JJ. The symptom intensity scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol 2006;33:2291-9
20. Devoulyte K, Sullivan MJ. Pain catastrophizing and symptom severity during upper respiratory tract illness. Clin J Pain 2003;19:125-33
21. Duong M, Subbarao P, Adelroth E, et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest 2008;133:404-11
22. Bollen KA. Structural equations with latent variables. New York (NY): Wiley Interscience Publications, J. Wiley & Sons; 1989
23. Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008 [April 15, epub ahead of print]
24. Kahn KL, Maclean CH, Wong AL, et al. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 2007;57:707-15
25. McDermott MF, Frenkel J. Hereditary periodic fever syndromes. Neth J Med 2001;59:118-25
26. Hilliquin P. Biological markers in inflammatory rheumatic diseases. Cell Mol Biol 1995;41:993-1006
27. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212
28. Yalcinkaya F, Cakar N, Acar B, et al. The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. Rheumatol Int 2007;27:517-22
29. Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006;54:1697-1700
30. Pithukpakorn M, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and dermatologic features, genetics, pathogenesis and therapy. Adv Dermatol 2006;22:67-90
31. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease specific quality of life in clinical trials. Can Med Assoc J 1986;134:889-95
32. Kirshner B, Guyatt GH. A methodological framework for assessing health indices. J Chronic Dis 1985;38:27-36
33. Van Oene CM, Van Reij EJ, Sprangers MA, et al. Quality-assessment of disease-specific quality of life questionnaires for rhinitis and rhinosinusitis: a systematic review. Allergy 2007;62:1359-71